Sandu Pharmaceuticals

Sandu Pharmaceuticals EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Sandu Pharmaceuticals (524703.BO) as of Oct 31, 2026 is 27.09 M INR. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 29.30 M INR — a change of -7.54% (lower).

EBITDA

27.09 MINR

YoY

-7.54%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Sandu Pharmaceuticals is 2026 27.09 M INR. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Sandu Pharmaceuticals was 2025 29.30 M INR. It decreases by -7.54% lower compared to the previous year.

The Sandu Pharmaceuticals EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2019
20.91 M INR
Jan 1, 2020
14.53 M INR
Jan 1, 2021
21.59 M INR
Jan 1, 2022
28.74 M INR
Jan 1, 2023
28.13 M INR
Jan 1, 2024
27.19 M INR
Jan 1, 2025
29.30 M INR
Jan 1, 2026
27.09 M INR
The Sandu Pharmaceuticals EBITDA history
YEAREBITDAYoY
27.09 MINR-7.54%
29.30 MINR+7.74%
27.19 MINR-3.34%
28.13 MINR-2.12%
28.74 MINR+33.12%
21.59 MINR+48.57%
14.53 MINR-30.51%
20.91 MINR-15.22%
24.67 MINR+8.28%
22.78 MINR+4.61%
21.78 MINR+29.59%
16.81 MINR+4.78%
16.04 MINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Sandu Pharmaceuticals Stock analysis

What does Sandu Pharmaceuticals do? Sandu Pharmaceuticals Ltd is a Mumbai-based company operating in the Consumer Staples sector, specifically within the consumer products industry. Listed on September 26, 1994, the firm manufactures and markets Ayurvedic medicines. Its product portfolio spans digestive health, immunity, muscle and bone health, respiratory health, and general wellness. Specific offerings address conditions such as constipation, hyperacidity, asthma, and colds, while also covering female, male, and mother-and-child wellness. The company utilizes in-house know-how from Sandu Brothers Private Limited for production and distributes its goods, including immunity kits and power herbs, through e-commerce marketplaces. Sandu Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sandu Pharmaceuticals stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Sandu Pharmaceuticals is 27.09 M INR in 2026.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Sandu Pharmaceuticals changed from 29.30 M INR to 27.09 M INR, representing a -7.54% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Sandu Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Sandu Pharmaceuticals historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Sandu Pharmaceuticals

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Sandu Pharmaceuticals